Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is based in Burlingame, California.…
Enliven Therapeutics Stock In Focus After Wider Loss And FDA Trial Alignment
Enliven Therapeutics (NASDAQ: ELVN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 65 employees.
The shares were at 46.53 USD on 20 November 2026, up 163.9% over 52 weeks. Its 52-week range is 14.79 USD to 62.32 USD: the price is 25.3% below the high and 214.7% above the low.
Its market capitalisation is 3.42B USD.
Enliven Therapeutics reports return on equity of -22.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 883.04M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 74.33 USD is 59.8% above the current price. The next earnings report is expected on 2 March 2027.